相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab
D. R. Shepard et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Sorafenib as a second-line and sequential therapy for patients with metastatic renal cell carcinoma (mRCC): Analysis for safety and activity on sunitinib progressive pts
J. Sepulveda et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Safety and Efficacy Results of the Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program in North America
Walter M. Stadler et al.
CANCER (2010)
Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma
Camillo Porta et al.
CANCER TREATMENT REVIEWS (2010)
A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01
Joaquim Bellmunt et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2010)
Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma
Holger Gerullis et al.
MEDICAL ONCOLOGY (2010)
Sequential Therapy With Sorafenib and Sunitinib in Renal Cell Carcinoma
Arkadiusz Z. Dudek et al.
CANCER (2009)
Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
Marta Paez-Ribes et al.
CANCER CELL (2009)
SEQUENTIAL USE OF THE TYROSIN KINASE INHIBITORS SORAFENIB AND SUNITINIB
R. Heuer et al.
EUROPEAN UROLOGY SUPPLEMENTS (2009)
Phase II Study of Sorafenib in Patients With Sunitinib-Refractory Metastatic Renal Cell Cancer
Giuseppe Di Lorenzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Sequential Sorafenib and Sunitinib for Renal Cell Carcinoma
M. P. Sablin et al.
JOURNAL OF UROLOGY (2009)
Sunitinib Treatment for Patients with Advanced Clear-Cell Renal-Cell Carcinoma after Progression on Sorafenib
Kaja Zimmermann et al.
ONCOLOGY (2009)
Sequential Use of the Tyrosine Kinase Inhibitors Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma: A Retrospective Outcome Analysis
Christian Eichelberg et al.
EUROPEAN UROLOGY (2008)
Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma
Naeem Bhojani et al.
EUROPEAN UROLOGY (2008)
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy
Ila Tamaskar et al.
JOURNAL OF UROLOGY (2008)
Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer et al.
LANCET (2008)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
A large open-label, non-comparative, phase III study of the multi-targeted kinase inhibitor sorafenib in European patients with advanced renal cell carcinoma
J. Beck et al.
EJC SUPPLEMENTS (2007)
Sunitinib in patients with metastatic renal cell carcinoma
Robert J. Motzer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase II placebo-controlled randomized discontinuation trial of sorafnib in patients with metastatic renal cell carcinoma
Mark J. Ratain et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
